Record Q1 growth, but guidance conservative pending geopolitical clarity

Delivered revenue ₹433.6 Cr, CFO stated exact match.

Delivered PAT ₹61.0 Cr (14.0% margin), CFO stated 14.1%; rounding variance.

Gross margin 37.9% vs 30% FY26; EBITDA margin 20.8% stated, supported by 37.9% gross margin.

Management explicitly stated temporary benefits, excluding from FY27 guidance.

Stated; no external verification, but consistent with export growth despite disruptions.

Management confirmed Q1 EBITDA positive from Mahad; utilization jump substantial but plausible given capex.

Mahad turned sustainably profitable Q1 after COVID/shutdown losses; management signaling caution on FY27 (70% EBITDA growth floor guidance, below Q1's exceptional trajectory) due to geopolitical headwinds.

Using debottlenecking (minor expense) to lift existing capacity 50–70%. Lubricant additives first: 50–70% boost next 2–3 months; antibacterial drug 60–90 days to plant commissioning post-sample approval (Jan 2027 target).

Strategic buildup for April (seasonal); ₹25 Cr from inventory realization + forex. Top customer ~₹55 Cr of ₹550 Cr FY27 projection. Excluding both from guidance to show normalized performance.

New process reduces steps 10→3; cost-competitive, first-mover advantage. Expecting 100+ tons/month post-approval; under NDA with multinational until samples green-lit.

Mahad Q1 EBITDA positive (no exact figure). FY27 guide ₹240–250 Cr excl. inventory/forex is conservative; minimum 70% EBITDA growth YoY. End-year utilization targeting 70%+.

Yes, 15–16% is conservative. Q1 benefited ₹25 Cr gains. Normalizing, expect 15–16%; 70% EBITDA growth floor guidance = minimum expectation given volatility.

15–20% conversion typical. ₹15 Cr R&D facility investment; ₹20 Cr speciality investment. Land already purchased at Mahad (20 acres surplus); newer chemistry using available land. 9 months for environmental clearance.

Excl. geopolitical/forex; midpoint ₹1,600 Cr = 4.3% growth vs Q1 annualized run-rate, conservative adjustment for Q2-Q4 seasonality and non-recurring Q1 benefits.

15–16% blended margin; excl. ₹25 Cr inventory/forex gains. Implies 70% YoY EBITDA growth minimum vs FY26.

Assumes geopolitical normalization; if volatility persists, margin upside risk if input costs ease; downside if pricing power erodes.

Land & infra ₹50–60 Cr; balance smaller investments across product lines. Expected to generate ₹500–550 Cr revenue at peak.

Product ID, site prep, regulatory approvals in progress; timing uncertain, expected within 18 months.

Top 10% customers = 24–25% of revenue; largest single customer ₹55 Cr of ₹550 Cr FY27 projection (~10%)

West Asia conflict reduced exports to some markets; crude/petrochem prices spiked Q1; Hormuz Strait disruptions. FY27 guidance assumes normalization.

40 products in R&D; only 15–20% expected to commercialize. Antibacterial drug approval, mining chemical scaling, are critical near-term catalysts.

Mahad 19,900-ton capacity jumped from 13% utilization (FY24, post-COVID) to 44% (FY26) to Q1 'sustainably profitable'. New product launches and market expansion required.

Acetone & phosphorus are petrochemical derivatives; prices volatile with crude. Q1 benefited from inventory gains (₹25 Cr) and FX tailwind; guidance excludes both.